Skip to content
Screener

Alumis Inc. ALMS Total Equity

Total Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$22.32B+28.0%
Amgen logo
AmgenAMGN
$11.69B+57.4%
Immunome logo
ImmunomeIMNM
$588.69M+91.7%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$486.72M+33.4%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$448.66M+329%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$597.21M+36.7%

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Reported directly by Alumis Inc. in its filing.

Tagged under the XBRL concept us-gaap:StockholdersEquity.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010
(in thousands, except share and per share amounts)March 31, 2026December 31, 2025
Preferred stock, $0.0001 par value; 50,000,000 shares authorized, zero shares issued and outstanding as of March 31, 2026 and December 31, 2025
Common stock, voting, $0.0001 par value; 492,815,092 voting shares authorized as of March 31, 2026 and December 31, 2025; 123,169,838 and 99,084,365 voting shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively129
Common stock, non-voting, $0.0001 par value; 7,184,908 non-voting shares authorized as of March 31, 2026 and December 31, 2025; 4,059,908 and 5,622,408 non-voting shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1
Additional paid-in capital1,562,4051,202,975
Accumulated other comprehensive income (loss)(467)188
Accumulated deficit(994,929)(901,876)
Total stockholders’ equity567,021301,297
Total liabilities and stockholders’ equity$671,588$411,940

Item 1. Financial Statements (Unaudited)

FAQ

What is Alumis Inc.'s total equity?
Alumis Inc. (ALMS) reported total equity of $567.02M in Q1 2026.
How has Alumis Inc.'s total equity changed year-over-year?
Alumis Inc.'s total equity increased by 236.9% year-over-year, from $168.31M to $567.02M.
What is the long-term trend for Alumis Inc.'s total equity?
Over 3 years (2022 to 2025), Alumis Inc.'s total equity has grown at a 15.6% compound annual growth rate (CAGR), from -$195.24M to $301.3M.
What does total equity mean?
Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.

Ask your AI about Alumis Inc.'s total equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude